Leerink Partners Cuts JNJ Price Target to $272

Leerink Partners has reiterated its Outperform rating on Johnson & Johnson (NYSE: JNJ) and adjusted its price target to $272 on October 14, 2026. This is a decrease from the previous target of $276.

Other Institutional Activity in Johnson & Johnson

Several other institutional investors have also made adjustments to their positions in Johnson & Johnson. BlackRock Inc. trimmed its stake by 1,280,271 shares, ending with 212,098,264 shares valued at about $54.2 billion. Vanguard Capital Management LLC increased its holdings by 626,400 shares, bringing its total to 157,226,374 shares worth approximately $40.2 billion. State Street Corporation added 293,661 shares, totaling 133,776,025 shares valued at about $34.2 billion. Similarly, Vanguard Portfolio Management LLC grew its stake by 857,431 shares, now holding 64,370,816 shares worth around $16.5 billion. Geode Capital Management, LLC decreased its holdings slightly by 76,912 shares, resulting in 59,086,417 shares valued at about $15.1 billion.

Johnson & Johnson Stock Up 0.5%

As of October 16, 2026, Johnson & Johnson's stock was recently trading around $255.26, which is below its 50-day moving average of $265.26 by about 3.8%. The stock is also below its 52-week high of $281.07 by approximately 9.2%, but it is above its 52-week low of $184.66 by about 38.2%. The average analyst price target for the stock is $279.41, suggesting further upside potential.

Recent Earnings

Johnson & Johnson reported trailing twelve-month revenue of approximately $99.3 billion, with an EPS of $6.59 and a net margin of 16.2%. The company has shown a revenue growth of 5.9% year-over-year. Its next earnings report is expected on January 26, 2027.

Insider Buying and Selling at Johnson & Johnson

Insider trading at Johnson & Johnson shows several notable sales. On August 6, 2026, Officer Elizabeth Forminard sold 15,918 shares worth approximately $4.1 million. CEO Joaquin Duato sold 123,291 shares valued at about $32.2 million on August 13, 2026. Additionally, Officer Jennifer L. Taubert sold 15,000 shares at an average price of $263.36, totaling around $3.9 million on August 17, 2026. Timothy Schmid, another officer, sold 33,597 shares on September 2, 2026, for about $9.2 million at an average price of $274.74.

Analysts Set New Price Targets

On October 14, 2026, RBC Capital maintained its Outperform rating with a target of $280, while Wells Fargo also maintained its Overweight rating with a target of $275. Earlier, on October 6, 2026, RBC Capital had set a target of $290, and Guggenheim reiterated a Buy rating with a target of $287. The consensus among analysts suggests a strong outlook for Johnson & Johnson, with a mean price target of $279.41 across 22 opinions.

About Johnson & Johnson

Johnson & Johnson, based in New Brunswick, NJ, is a global leader in healthcare. The company develops and sells a wide range of products, operating mainly in two segments: Innovative Medicine and MedTech. Its strong market presence and diverse product offerings are key factors in its robust financial performance.

Bottom Line

Investors should keep an eye on Johnson & Johnson as it approaches its earnings report on January 26, 2027. The adjustments in analyst ratings and price targets may influence market sentiment moving forward.